Fairvalue-Calculator Fairvalue-Calculator
EN DE

Dimerix Limited (DXB) Fair Value & Analysis

Healthcare · AU · Market cap A$105M

PriceA$0.2050
Fair ValueA$0.1000
Upside-51.2%
Quality95/100
Evidence: Medium Range A$0.0800 – A$0.1300

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Dimerix Limited (DXB) currently trades at A$0.2050, while our model-based Fair Value estimate is A$0.1000 — implying the stock looks roughly 51.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Dimerix Limited (DXB) undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.1000 versus a price of A$0.2050 — about −51% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DXB?
Our 21-model fair value for Dimerix Limited is A$0.1000 (as of Jun 24, 2026), built from audited fundamentals. The current price is A$0.2050.
What is the quality score of DXB?
Dimerix Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.